BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 2125377)

  • 1. Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients.
    Reed BR; Chen AB; Tanswell P; Prince WS; Wert RM; Glaesle-Schwarz L; Grossbard EB
    Thromb Haemost; 1990 Oct; 64(2):276-80. PubMed ID: 2125377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non neutralizing antibodies to tissue type plasminogen activator in the serum of acute myocardial infarction patients treated with the recombinant protein.
    Cugno M; Cicardi M; Colucci M; Bisiani G; Merlini PA; Spinola A; Paonessa R; Agostoni A
    Thromb Haemost; 1996 Aug; 76(2):234-8. PubMed ID: 8865537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA.
    Holvoet P; Cleemput H; Collen D
    Thromb Haemost; 1985 Oct; 54(3):684-7. PubMed ID: 3937265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-t-PA antibodies in acute myocardial infarction after thrombolysis with rt-PA.
    Cugno M; Castelli R; Bisiani G; Griffini S; Meroni PL
    Eur J Intern Med; 2010 Feb; 21(1):25-9. PubMed ID: 20122609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator].
    Verstraete M; Bory M; Collen D; Erbel R; Lennane RJ; Mathey D; Michels HR; Schartl M; Uebis R; Bernard R
    Klin Wochenschr; 1988; 66 Suppl 12():77-85. PubMed ID: 3126348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Intravenous infusion of recombinant tissue-type plasminogen activator (rt-PA) and urokinase in acute myocardial infarct: intermediate results of the G.A.U.S. study (German Activator Urokinase Study)].
    Neuhaus KL; Tebbe U; Gottwik M; Weber MA; Feuerer W; Niederer W; Haerer W; Praetorius F; Grosser KD; Huhmann W
    Klin Wochenschr; 1988; 66 Suppl 12():102-8. PubMed ID: 3126339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
    Collen D; Stassen JM; Yasuda T; Refino C; Paoni N; Keyt B; Roskams T; Guerrero JL; Lijnen HR; Gold HK
    Thromb Haemost; 1994 Jul; 72(1):98-104. PubMed ID: 7974384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of fibrinolytic capacity by a combined assay system for tissue-type plasminogen activator antigen and function using monoclonal anti-tissue-type plasminogen activator antibodies.
    Wojta J; Turcu L; Wagner OF; Korninger C; Binder BR
    J Lab Clin Med; 1987 Jun; 109(6):665-71. PubMed ID: 3108431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A sensitive solid-phase immunosorbent assay for tissue-type plasminogen activator activity in plasma using trinitrobenzoylated poly-D-lysine as a stimulator for plasminogen activation.
    Petersen LC; Handest P; Brender J; Selmer J; Jørgensen M; Thorsen S
    Thromb Haemost; 1987 Apr; 57(2):205-11. PubMed ID: 3110997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of fibrin-like stimulators on the activation of plasminogen by tissue-type plasminogen activator (t-PA)--studies with active site mutagenized plasminogen and plasmin resistant t-PA.
    Lijnen HR; Van Hoef B; De Cock F; Collen D
    Thromb Haemost; 1990 Aug; 64(1):61-8. PubMed ID: 2148848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The absence of a procoagulant effect after TNK-t-PA: a comparison with streptokinase and rt-PA].
    De Marco E; Andreotti F; van de Greef W; Quaranta G; Biasucci LM; Kol A; Maseri A; Rebuzzi AG
    Cardiologia; 1998 Nov; 43(11):1209-13. PubMed ID: 9922587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer.
    Grøndahl-Hansen J; Agerlin N; Munkholm-Larsen P; Bach F; Nielsen LS; Dombernowsky P; Danø K
    J Lab Clin Med; 1988 Jan; 111(1):42-51. PubMed ID: 3121772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
    Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of cardiac output on peak t-PA plasma levels in patients receiving thrombolytic therapy with recombinant tissue-type plasminogen activator--correlation with patency rate.
    Huber K; Beckmann R; Probst P; Rauscha F; Kaindl F; Binder BR
    Thromb Haemost; 1993 Jan; 69(1):45-9. PubMed ID: 8446938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mapping of epitopes on human tissue-type plasminogen activator with recombinant deletion mutant proteins.
    van Zonneveld AJ; Veerman H; Brakenhoff JP; Aarden LA; Cajot JF; Pannekoek H
    Thromb Haemost; 1987 Feb; 57(1):82-6. PubMed ID: 2438798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombolysis in myocardial infarction (TIMI): update 1987.
    Mueller HS
    Klin Wochenschr; 1988; 66 Suppl 12():93-101. PubMed ID: 3126350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of antigen and activity of recombinant tissue-type plasminogen activator after infusion in healthy volunteers.
    Seifried E; Tanswell P; Rijken DC; Barrett-Bergshoeff MM; Su CA; Kluft C
    Arzneimittelforschung; 1988 Mar; 38(3):418-22. PubMed ID: 3132929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clopidogrel-rt-PA-heparin combination in the treatment of acute myocardial infarction.
    Bassand JP; Cariou R; Grollier G; Kragten J; Wolf JE; Heyndrickx GR
    Semin Thromb Hemost; 1999; 25 Suppl 2():69-75. PubMed ID: 10440428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerated intravenous dosing of recombinant tissue-type plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction.
    Gurbel PA; Anderson RD; MacCord CS; Scott H; Serebruany V; Herzog WR
    Coron Artery Dis; 1994 Nov; 5(11):929-36. PubMed ID: 7719525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial of intraoperative, intracisternal tissue plasminogen activator for the prevention of vasospasm.
    Findlay JM; Kassell NF; Weir BK; Haley EC; Kongable G; Germanson T; Truskowski L; Alves WM; Holness RO; Knuckey NW
    Neurosurgery; 1995 Jul; 37(1):168-76; discussion 177-8. PubMed ID: 8587685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.